How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

This Perspective examines the role of AI-based image analysis when applied to stem cell-derived models. We developed an optogenetic tool based on tetanus neurotoxin — a protease that cleaves the ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals insiders reported 6 transactions totaling $589,430.56. Activity included 2 tax payments, 2 sales, and 2 stock awards between July and August 2026. View more Major Holders ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...